MONARCH vs MOBILITY: Similar Efficacy With Sarilumab ± MTX in MTX-IR/INT RA

November 5-9, 2020; Virtual Meeting

In cross-trial post hoc analysis with mixed-effect model repeated measure adjustment, no evident differences in Week 24 endpoints (CDAI, DAS28-CRP, CRP, hemoglobin, pain VAS, FACIT-Fatigue) between patients receiving sarilumab with vs without MTX.

Format: Microsoft PowerPoint (.ppt)
File Size: 164 KB
Released: November 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Related Content

CCO highlights from Stanley Cohen, Sheetal Desai, Eric Ruderman on JAKs before and after DMARD failure, treat-to-target, shared decision making

Released: November 13, 2020

ACR 2020: SEAM-RA trial on switch to ETN or MTX monotherapy vs continued combination therapy in RA patients with stable remission, as reported by CCO

Released: November 12, 2020

San Antonio cohort study from ACR 2020 on potential cardiotoxicity of hydroxychloroquine in patients with rheumatoid arthritis (RA), as reported by CCO

Released: November 11, 2020

Pharmacogenomics biomarkers may be useful in predicting the response to methotrexate among patients with early RA in a machine learning model: ACR 2020 study reported by CCO

Released: November 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue